Out of stock sold out
Biotech

After Lilly-Kelonia deal, are any in vivo biotechs left to buy?

Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking to slow due to a shortage of viable acquisition targets.
Will Maddox Apr 24, 2026 9:30am
A collection of the fungus among us

Compass, Usona and Transcend score priority vouchers amid psychedelic push

Apr 24, 2026 3:51pm
Lung

Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs

Apr 24, 2026 7:08am
computer and clinical science AI data

WCG acquires The Contract Network to streamline clinical trials

Apr 24, 2026 1:38pm
Parachute over a desert

Helus CEO out after two months—Chutes & Ladders

Apr 24, 2026 8:30am
hearing audio waves
Favicon Fierce Pharma

Regeneron ushers in new era with inaugural gene therapy approval

Apr 23, 2026 3:22pm
More News
Fierce Pharma

Roche exec: Giredestrant may become company’s largest product

Apr 23, 2026 2:52pm

Pfizer cans work on next-gen conjugate in cancer patients

Apr 23, 2026 11:20am

Kurma closes €215M Europe-focused fund to spend on 20 biotechs

Apr 23, 2026 8:30am

Roche CEO gives 3 reasons for sitting out Big Pharma M&A spree

Apr 23, 2026 5:18am